Micafungin is an antimycotic drug and represents an importantaddition to the available therapies for the treatment of systemic fungalinfections. Micafungin is used: in the treatment of invasive candidiasis,oesophageal and prophylaxis of Candida infections. Itinhibits, in a non-competitive way, the synthesis of 1,3-β-D-glucan, acomponent of fungal cell wall and is rapidly distributed into the tissues.It has a high-rate respectful bond with plasma protein, which isindependent from the concentration of the drug. It is metabolizedthrough the liver, being not subject to intense metabolic transformationsuntil the excretion. There is no evidence of systemic accumulationafter repeated use. The steady-state is reached in 4-5 days.Medical records examined at the pharmacy of Marsala Hospital highlightthat, from 01/06/2014 to 01/08/2014, in this hospital 12 vialswere used by the hospitalized patients in the Department ofIntensive Care: 8 patients between 75 and 83 years old had a bodyweight (BW) higher than 40 kg; 3 patients between 40 and 60 yearsof age had a BW higher than 40 kg, and one 17 year-old patient hada BW of 40 kg. Two patients needed a dose increase, while for theother 10 patients the first dose resulted sufficient. Mycamine® wasused for the treatment of hypovolemic post-operative shock. Themost recorded adverse reactions were anemia, hypokalaemia, hypomagnesaemia,phlebitis, nausea, liver problems. Given the differentweight of the subjects, the dosage was different.
|Numero di pagine||3|
|Rivista||JOURNAL OF BIOLOGICAL RESEARCH|
|Stato di pubblicazione||Published - 2016|
All Science Journal Classification (ASJC) codes